Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
CNY 4.11
(2.49%)
CNY 4.11
(2.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.64 Billion CNY | 9.33% |
| 2022 | 2.42 Billion CNY | -1.28% |
| 2021 | 2.45 Billion CNY | 3.58% |
| 2020 | 2.36 Billion CNY | -14.83% |
| 2019 | 2.78 Billion CNY | 4.18% |
| 2018 | 2.66 Billion CNY | 27.67% |
| 2017 | 2.09 Billion CNY | 61.2% |
| 2016 | 1.29 Billion CNY | 83.17% |
| 2015 | 708.09 Million CNY | 57.86% |
| 2014 | 448.56 Million CNY | 25.38% |
| 2013 | 357.77 Million CNY | -14.82% |
| 2012 | 420.01 Million CNY | 17.14% |
| 2011 | 358.54 Million CNY | -22.73% |
| 2010 | 464.01 Million CNY | 42.98% |
| 2009 | 324.52 Million CNY | 63.53% |
| 2008 | 198.45 Million CNY | 112.39% |
| 2007 | 93.44 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 623.61 Million CNY | -22.95% |
| 2024 Q3 | 562.26 Million CNY | -9.84% |
| 2024 Q1 | 809.39 Million CNY | 21.76% |
| 2023 Q3 | 654.46 Million CNY | 2.66% |
| 2023 Q1 | 691.02 Million CNY | 8.31% |
| 2023 FY | 2.64 Billion CNY | 9.33% |
| 2023 Q4 | 664.76 Million CNY | 1.57% |
| 2023 Q2 | 637.49 Million CNY | -7.75% |
| 2022 Q1 | 552.69 Million CNY | -11.83% |
| 2022 Q4 | 638 Million CNY | 0.73% |
| 2022 Q2 | 597.65 Million CNY | 8.14% |
| 2022 FY | 2.42 Billion CNY | -1.28% |
| 2022 Q3 | 633.39 Million CNY | 5.98% |
| 2021 Q1 | 649.32 Million CNY | 18.55% |
| 2021 Q3 | 604.88 Million CNY | 5.73% |
| 2021 Q4 | 626.83 Million CNY | 3.63% |
| 2021 FY | 2.45 Billion CNY | 3.58% |
| 2021 Q2 | 572.09 Million CNY | -11.89% |
| 2020 Q4 | 547.74 Million CNY | -16.82% |
| 2020 Q3 | 658.53 Million CNY | 11.6% |
| 2020 Q2 | 590.07 Million CNY | 3.16% |
| 2020 Q1 | 571.99 Million CNY | -14.57% |
| 2020 FY | 2.36 Billion CNY | -14.83% |
| 2019 FY | 2.78 Billion CNY | 4.18% |
| 2019 Q4 | 669.52 Million CNY | -4.16% |
| 2019 Q3 | 698.56 Million CNY | 1.76% |
| 2019 Q2 | 686.51 Million CNY | -5.46% |
| 2019 Q1 | 726.13 Million CNY | 17.59% |
| 2018 Q3 | 617.16 Million CNY | -8.16% |
| 2018 FY | 2.66 Billion CNY | 27.67% |
| 2018 Q1 | 762.58 Million CNY | 25.22% |
| 2018 Q2 | 672.01 Million CNY | -11.88% |
| 2018 Q4 | 617.52 Million CNY | 0.06% |
| 2017 FY | 2.09 Billion CNY | 61.2% |
| 2017 Q2 | 492.32 Million CNY | 9.41% |
| 2017 Q4 | 608.98 Million CNY | 12.87% |
| 2017 Q1 | 449.96 Million CNY | 6.62% |
| 2017 Q3 | 539.53 Million CNY | 9.59% |
| 2016 Q3 | 377.61 Million CNY | 32.18% |
| 2016 FY | 1.29 Billion CNY | 83.17% |
| 2016 Q4 | 422.02 Million CNY | 11.76% |
| 2016 Q2 | 285.67 Million CNY | 34.94% |
| 2016 Q1 | 211.7 Million CNY | 8.99% |
| 2015 Q1 | 120.59 Million CNY | 2.55% |
| 2015 Q3 | 217.82 Million CNY | 24.16% |
| 2015 FY | 708.09 Million CNY | 57.86% |
| 2015 Q4 | 194.24 Million CNY | -10.82% |
| 2015 Q2 | 175.43 Million CNY | 45.47% |
| 2014 Q4 | 117.6 Million CNY | 17.75% |
| 2014 FY | 448.56 Million CNY | 25.38% |
| 2014 Q1 | 110.51 Million CNY | 11.91% |
| 2014 Q2 | 120.58 Million CNY | 9.12% |
| 2014 Q3 | 99.87 Million CNY | -17.18% |
| 2013 Q4 | 98.74 Million CNY | 25.14% |
| 2013 FY | 357.77 Million CNY | -14.82% |
| 2013 Q1 | 96.15 Million CNY | 11.75% |
| 2013 Q2 | 83.96 Million CNY | -12.69% |
| 2013 Q3 | 78.91 Million CNY | -6.01% |
| 2012 FY | 420.01 Million CNY | 17.14% |
| 2012 Q3 | 110.07 Million CNY | -10.29% |
| 2012 Q1 | 101.17 Million CNY | 19.79% |
| 2012 Q4 | 86.05 Million CNY | -21.83% |
| 2012 Q2 | 122.71 Million CNY | 21.29% |
| 2011 Q3 | 66.15 Million CNY | -30.06% |
| 2011 Q4 | 84.45 Million CNY | 27.67% |
| 2011 Q2 | 94.58 Million CNY | -16.56% |
| 2011 FY | 358.54 Million CNY | -22.73% |
| 2011 Q1 | 113.35 Million CNY | 0.16% |
| 2010 Q2 | 122 Million CNY | 1.51% |
| 2010 Q1 | 120.19 Million CNY | 0.0% |
| 2010 Q4 | 113.17 Million CNY | 4.17% |
| 2010 Q3 | 108.64 Million CNY | -10.95% |
| 2010 FY | 464.01 Million CNY | 42.98% |
| 2009 FY | 324.52 Million CNY | 63.53% |
| 2008 FY | 198.45 Million CNY | 112.39% |
| 2007 FY | 93.44 Million CNY | 0.0% |